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Abstract
Hypothalamic dysfunction is a rarely diagnosed endocrine disorder resulting from various pathological processes affecting this brain
region. It is characterized by a complex clinical manifestation, including headaches, abnormal regulation of various behaviours, abnormal-
ities in sleeping and thermoregulation, and inappropriate secretion of many hormones. In our paper, we report the case of a 29-year-old
female in whom hypothalamic dysfunction was induced by delivery complications. Accurate diagnosis of this syndrome required com-
plex laboratory and imaging tests. The disease-related obesity was resistant to conventional treatment (diet and pharmacotherapy) and
only bariatric surgery caused a reduction of body mass. The described patient is the first with postpartum hypothalamic dysfunction in
whom plasma levels of adipokines, neuropeptides, and alimentary tract hormones contributing to physiological regulation of food intake
were assessed. (Pol J Endocrinol 2010; 61 (4): 396–399)
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Streszczenie
Zaburzenia czynności podwzgórza stanowią rzadko rozpoznawaną jednostkę kliniczną, stanowiącą konsekwencję różnych procesów
patologicznych toczących się w obrębie tej struktury mózgu. Charakteryzuje ją złożony obraz kliniczny, na który składają się bóle głowy,
nieprawidłowa regulacja łaknienia i pragnienia, zaburzenia snu i termoregulacji oraz nieprawidłowe wydzielanie hormonów. W niniej-
szym artykule opisano przypadek 29-letniej kobiety, u której doszło do rozwoju zaburzeń czynności podwzgórza w następstwie powi-
kłań okołoporodowych. Postawienie prawidłowego rozpoznania wymagało wykonania wielu oznaczeń laboratoryjnych i przeprowadze-
nia badań obrazowych. Otyłość, która wystąpiła u pacjentki, wykazywała oporność na klasyczne leczenie (dietetyczne i farmakologiczne)
i dopiero leczenie bariatryczne spowodowało redukcję masy ciała. Opisywana pacjentka jest pierwszą chorą z poporodową dysfunkcją
podwzgórza, u której wykonano oznaczenia stężeń w osoczu adipokin, neuropeptydów i hormonów przewodu pokarmowego uczestni-
czących w fizjologicznej regulacji poboru pokarmu. (Endokrynol Pol 2010; 61 (4): 396–399)
Słowa kluczowe: poporodowe zaburzenia czynności podwzgórza, obraz kliniczny, otyłość, patogeneza, leczenie
Introduction
Hypothalamic dysfunction, formerly known as hypo-
thalamosis or diencephalosis, is a rarely diagnosed en-
docrine disorder which is a consequence of abnormal
activity of the hypothalamus [1, 2]. The hypothalamus
is one of the most crucial regions of the brain, which
controls hunger, thirst, body temperature, and circadi-
an cycles and is considered a link between the nervous
and endocrine systems [3–5]. Although hypothalamic
dysfunction may result from various pathological pro-
cesses within the central nervous system, most cases of
this disorder described to date concern young women
who underwent a difficult delivery or abortion, and for
these cases some authors use the Latin term hypothala-
mosis post graviditate. Other disorders leading to the
development of diencephalosis are: traumas, intoxica-
tions, or infections [1, 6]. The clinical manifestation of
hypothalamic dysfunction differs markedly between
patients. However, the most frequently reported symp-
toms include obesity, abnormal feeding behaviour (an-
orexia or excessive eating), a disturbed regulation of
thirst (polydipsia or adipsia), vegetative dysfunctions
(headaches, cramping abdominal pains, and diaphore-
sis), sleeping disturbances (narcolepsy, insomnia, peri-
odic attacks of sleep), abnormal thermoregulation
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(hypo- or hyperthermia), disturbances in the psychic
sphere (neurasthenia, depression), and abnormal secre-
tion of various hormones, especially vasopressin or ox-
ytocin deficiency, hypogonadism, or hyperprolacti-
naemia [2].
In recent years, hypothalamic dysfunction has been
diagnosed very rarely, which may be explained by
a better understanding of the pathophysiological pro-
cesses within the hypothalamus and its surrounding
structures, an improvement in brain imaging proce-
dures, and better care of females during the peripartal
period. In some cases, the cause of a rare diagnosis may
also be the unclear definition and lack of uniform diag-
nostic criteria of this disorder. For these reasons, some
authors even reject the existence of this clinical entity,
which, in our opinion, is not the case. In the present
study, we reported a 29-year-old woman with deliv-
ery-induced hypothalamic dysfunction. Apart from the
description of the patient’s clinical picture, our study is
the first which has determined plasma levels of adipok-
ines, neuropeptides, and alimentary tract hormones
contributing to a physiological regulation of food in-
take and body mass in any individual suffering from
this syndrome. Their measurements enabled us to ver-
ify the hypothesis that hypothalamic dysfunction is as-
sociated with a disturbed function of adipose tissue or
with abnormal activity of the gut-brain axis.
Patient’s presentation
A 29-year-old woman was admitted to our clinic in or-
der to determine the cause of a dramatic increase in body
mass. Before first pregnancy in 2005 her body mass was
55 kg and her body mass index (BMI) was 19.5 kg/m2.
During the first pregnancy she felt well and no compli-
cations were noticed until delivery. Labour was com-
plicated by the incorrect position of the foetus. For this
reason and because of insufficient progress of the la-
bour, the gynaecologists decided to perform a caesare-
an section. As a result of this operation and increased
haemorrhage in the third stage of labour, the patient
lost about two litres of blood and blood pressure de-
creased to 80/60 mm Hg. Consequently, the patient had
to be given erythrocyte mass and fresh frozen plasma
transfusions together with crystalloids and colloids to
restore the appropriate volume of the vascular bed. Al-
though during the first pregnancy her weight gain was
12 kg, after the labour it decreased only by 8 kg, and
almost at once started to rise. During the following
11 months preceding the patient’s second pregnancy,
her body mass increased from 59 to 69 kg, and BMI from
20.9 to 24.4 kg/m2. The weight gain was accompanied
by headaches and abdominal pains of different local-
ization and intensity, dizziness, heart palpitations, trem-
or, excessive sweating, alternate periods of oligodipsia
and polydipsia, and abnormalities in menstrual cycle,
which were absent before the first gestation. Eleven
months after her first gestation, the patient became preg-
nant for the second time. Although the above-men-
tioned symptoms did not disappear, their intensity re-
mained at a similar level throughout the pregnancy.
Gestation, during which weight gain reached 5 kg, end-
ed in the second caesarean section performed because
of obstetric indications. After delivery, the patient’s body
mass, which returned to the pregestational value, start-
ed dramatically increasing (20 kg within six months).
The above-described symptoms became much more
pronounced than in the period between both pregnan-
cies. Moreover, the patient started to experience new
symptoms, such as alternative periods of binge eating
and fasting, paroxysmal insomnia, attacks of flushing
of the face and neck, and almost complete loss of libi-
do. Lactation was undisturbed and therefore she breast-
fed her child for four months. After lactation, her menses
became sparse and irregular, and therefore oral contra-
ceptive pills, containing ethinyl estradiol (35 mg) and
norgestimate (250 mg) were prescribed. An inacceptable
increase in body mass led to depressive symptoms and
to several-week periods of dramatic reduction in food
consumption and very intense exercise. Despite diet
restrictions and regular physical activity, the body mass
did not change, and therefore the patient was prescribed
(by a general practitioner) sibutramine. Two months lat-
er, due to lack of effect, sibutramine was replaced with
orlistat, which also did not result in a reduction in body
mass. The significant weight gain of 20 kg since the sec-
ond labour (BMI increased to 31.5 kg/m2), with no signif-
icant effect of both non-pharmacological and pharma-
cological treatment, and the range of accompanying com-
plaints meant that the patient was admitted to our clinic.
On admission, apart from the increased waist cir-
cumference (114 cm), the patient did not have other
abnormal characteristic for metabolic syndrome (blood
pressure — 125/80, triglycerides — 134 mg/dL, HDL cho-
lesterol — 52 mg/dL, plasma fasting glucose — 85 mg/dL).
Two-hour post-challenge plasma glucose, plasma insu-
lin, and homeostatic model assessment (HOMA) ratio
were, respectively, 132 mg/dL, 10.5 mIU/L, and 2.2. Dur-
ing hospitalization, we performed complex diagnostics
including both hormonal and imaging tests. We excluded
hypothyroidism (TSH — 0.791 mU/L, fT4 — 0.96 ng/dL,
fT3 — 3.66 pg/mL), Cushing syndrome (cortisol suppres-
sion after 1 mg of dexamethasone to 0.99 mg/dL; urine
free cortisol — 68 and 62 mg/day, reference values: 20–90;
plasma DHEA-S — 242.6 mg/dL, reference values: 80–450),
polycystic ovary syndrome (normal levels of testoster-
one, androstendione, normal free androgen index, lack
of clinical manifestations of androgen excess and of typi-
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cal ultrasonographic features in the ovaries), congeni-
tal adrenal hyperplasia (17-hydroxy-progesterone at
baseline — 0.34 ng/mL, and after Synacthen adminis-
tration — 1.14 ng/mL), insulinoma (fasting insulin
— 10.2 mIU/L, reference range: 5–25; fasting C-peptide
— 2.65 ng/mL, reference range: 0.55–2.9; the normal result
of the fasting test), GH deficiency (IGF-I levels within
the reference range — 137 ng/mL; the normal response
of GH to insulin-induced hypoglycaemia (an increase
from 1.7 to 11.2 mg/L) and pseudohypoparathyroidism
(negative history, normal PTH levels). We also exclud-
ed pituitary disorders induced by pregnancy or labour
(Sheehan’s syndrome and hypophysitis). Plasma osmo-
larity (287 mOsm/kg H2O) and plasma sodium
(137 mmol/L) were within normal limits. With the excep-
tion of a small haemangioma located in the left cerebellar
lobe, no pathological changes on magnetic resonance
imaging of the brain and pituitary were found. Adiponec-
tin concentration (10.2 mg/mL) was lower than in patients
with alimentary-induced obesity (18.0 ± 2.5 mg/mL).
Ghrelin (49.4 ng/mL), obestatin (115.6 ng/mL), peptide
YY (10.0 ng/mL), neuropeptide Y (750.8 ng/mL), gluca-
gon-like peptide-1 (51.5 pg/mL), insulin (14.8 mIU/L),
resistin (4.5 ng/mL), and leptin (21.2 ng/mL) levels did
not differ from those observed previously in patients
with simple obesity, treated in our departments. Ad-
ministration of piracetam (4.8 g/day) partially improved
the patient’s general feeling and reduced intensity of
complaints. Our eight-month trial of a treatment with
orlistat (360 mg/daily in three doses) plus sibutramine
(15 mg/day once daily), combined with lifestyle modifi-
cation and behavioural therapy, resulted in only a small
(about 5%) and transient reduction of body mass. The
lack of success of traditional therapy made the patient
decide to undertake bariatric surgery treatment with
a Roux-en-Y gastric bypass. Although a 10% reduction
in body weight was observed during the first 6 months
after operation, presently the patient’s weight is almost
18% below the maximal weight. Because of the risk of
iron deficiency, vitamin B12 deficiency, and impaired
vitamin D and calcium absorption, the patient is sup-
plemented with these nutrients. Apart from occasional
diarrhoea, no other side effects of the bariatric inter-
vention are reported. Her body mass is 73 kg, BMI
25.6 kg/m2, and waist circumference 94 cm. Although
she still experiences periodic headaches, dizziness, dia-
phoresis, insomnia, depressive moods, and reduced li-
bido, the frequency and intensity of these symptoms is
significantly less than previously.
Discussion
Pregnancy is associated with an increased secretion of
tropic hormones, leading to enhanced sensitivity of the
hypothalamic cells to ischaemia [7]. If, during pregnan-
cy or labour, the blood supply is disturbed by a signifi-
cant loss of blood, metabolically active cells within this
region may become transiently or persistently damaged
[2]. This was the case in our subject, who underwent
a long delivery with a massive haemorrhage.
Interestingly, no significant changes in the secretion
of prolactin and activity of the GH-IGF-1, hypothalam-
ic-pituitary-adrenal, hypothalamic-pituitary-thyroid,
and hypothalamic-pituitary-ovarian axes were ob-
served. This finding clearly indicates that neither obe-
sity nor other complaints experienced by the patient
can be explained by abnormal hormonal secretion. This
possibly means that either the destruction was limited
to the hypothalamic regions involved in body mass con-
trol, or, and this explanation is more probably, the mech-
anisms responsible for the regulation of energy balance
are more prone to ischaemic destruction than those con-
trolling hormone synthesis and release. Therefore, prob-
ably no therapy targeted at these endocrine systems
would bring benefits to this individual.
It should be stressed that, despite hypothalamic
dysfunction, the patient managed to conceive within
a short period of time from her previous pregnancy.
This finding indicates that the presence of hypothalamic
dysfunction does not disqualify a patient from having
children. However, as the reported case shows, the sub-
sequent pregnancies and deliveries may exacerbate the
clinical course of this disease. Our patient responded
only weakly to the therapy with sibutramine and orl-
istat, even in the case when these agents were adminis-
tered in combination at their highest doses together with
non-pharmacological means of treatment (a low-calor-
ic diet, physical exercise, and behavioural therapy).
A visible effect was observed only after performing
a Roux-en-Y gastric bypass. This finding supports the
previous observations that bariatric surgery is the most
effective means of treatment of drug-resistant obesity,
associated with an acceptable number of adverse effects
[8, 9]. Although bariatric surgery is recommended for
subjects with BMI exceeding 35 kg/m2 [8, 9], our results
also evidenced its benefits in individuals with less se-
vere obesity coexisting with other disturbances.
Piracetam, the most commonly used nootropic drug,
being a cyclic derivative of gamma-aminobutyric acid,
administered at high doses reduced some symptoms in
our patient (drowsiness, flushing, diaphoresis) and re-
stored the correct eating and thirst behaviours. These
benefits may be attributed to piracetam-induced chang-
es in the physical properties of the plasma membrane
caused by increasing its fluidity and protecting the cell
against hypoxia, which is responsible for the antithrom-
botic, neuroprotective, and rheological properties of this
agent [10].
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Our study is the first one to investigate plasma lev-
els of hormones involved in the regulation of food in-
take in patients with postpartum hypothalamic dys-
function [11]. In the study, ghrelin, glucagon-like pep-
tide-1, obestatin, peptide YY, neuropeptide Y, and lep-
tin levels remained at a similar level as those in patients
with alimentary obesity. This suggests that either hy-
pothalamic dysfunction does not affect the release of
these hormones, or plasma levels of ghrelin, glucagon-
like peptide-1, obestatin, peptide YY, neuropeptide Y,
and leptin do not accurately reflect their local concen-
trations in the central nervous system. However, be-
cause hormonal analysis was performed only at base-
line conditions, we cannot exclude the existence of dis-
turbances in the postprandial secretion of these hor-
mones. The only exception was the very low level of
adiponectin, which suggests that this hormone may
contribute to the pathogenesis of postpartum hypotha-
lamic dysfunction. If so, adiponectin-targeted drugs,
being the subject of intense research [12], may provide
some benefits to patients with obesity induced by ab-
normal functioning of the hypothalamus. Our study
design did not allow us to exclude the association be-
tween postpartum hypothalamic dysfunction and ab-
normal functioning of the endocannabinoid, proopi-
omelanocortin, serotoninergic, and other systems in-
volved in the regulation of food intake and energy ex-
penditure, which is an interesting direction for further
research on patients with this disease.
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